Po-Shun Lee

54 year

Health Technology

Consumer Services

Profile

Po-Shun Lee is the founder of Critical Biologics Corp.
which was founded in 2006.
He worked as an Associate Medical Director at Vertex Pharmaceuticals, Inc. from 2010 to 2013.
From 2014 to 2019, he worked as the Chief Medical Officer & Executive Vice President at Proteostasis Therapeutics, Inc. Dr. Lee holds a doctorate degree from the University of Pennsylvania and an undergraduate degree from The Johns Hopkins University.

Former positions of Po-Shun Lee

Companies	Position	End
PROTEOSTASIS THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	2019-07-21
VERTEX PHARMACEUTICALS INCORPORATED	Corporate Officer/Principal	2012-12-31
Critical Biologics Corp. Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA.	Founder	-

See the detail of Po-Shun Lee's experience

Training of Po-Shun Lee

University of Pennsylvania	Doctorate Degree
The Johns Hopkins University	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Po-Shun Lee's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
VERTEX PHARMACEUTICALS INCORPORATED	Health Technology

Private companies	2
Critical Biologics Corp. Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA.	Health Technology
Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.	Health Technology